• If you are wondering whether Sarepta Therapeutics at US$20.80 is starting to look like value or still carries too much risk, the recent share price and fundamentals give you a lot to weigh up.
• The stock has been under pressure, with returns of 0.4% decline over 7 days, 9.9% decline over 30 days, 2.4% decline year to date, 43.0% decline over 1 year and 82.7% decline over 3 years, while the 5 year return sits at 71.3% decline.
• Recent news around Sarepta Therapeutics has focused on its position in the biotechnology space and ongoing attention from investors assessing its clinical and pipeline profile. This backdrop has kept sentiment sensitive, which helps explain why the share price has reacted so sharply to new developments.
• On Simply Wall St's valuation checks, Sarepta Therapeutics currently scores 2 out of 6. The next sections will walk through what different valuation methods are indicating about the stock and finish by looking at a broader way to think about its value story beyond the numbers alone.

Sarepta Therapeutics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Sarepta Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting its future cash flows and discounting them back to today using a required rate of return.

For Sarepta Therapeutics, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections in $. The latest twelve month free cash flow sits at about $86.9 million. Analyst and extrapolated estimates suggest free cash flow of $80.99 million in 2026 and $433 million in 2030, with intermediate years stepping up according to the projections Simply Wall St has compiled.

Rolling these projected cash flows forward and discounting them back, the model arrives at an estimated intrinsic value of about $72.72 per share. Compared to the current share price of $20.80, this implies the stock is about 71.4% undervalued on this particular set of assumptions.

DCF results always depend heavily on the cash flow forecasts and discount rate used, but on these inputs Sarepta Therapeutics screens as unusually cheap.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Sarepta Therapeutics is undervalued by 71.4%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Sarepta Therapeutics Price vs Earnings

For profitable companies, the P/E ratio is a common way to think about value because it connects what you pay for each share with the earnings that each share generates today. It gives you a quick sense of how many years of current earnings the market is pricing into the stock.

What counts as a “normal” P/E partly reflects expectations and risk. Higher expected earnings growth and lower perceived risk usually support higher P/E ratios, while lower growth expectations or higher risk tend to line up with lower P/E ratios.

Sarepta Therapeutics currently trades on a P/E of 33.75x. That sits above the Biotechs industry average P/E of 17.76x and above the peer group average of 3.13x. Simply Wall St’s “Fair Ratio” for Sarepta, at 10.74x, is a proprietary estimate of what the P/E might look like after considering factors such as earnings growth profile, industry, profit margins, market cap and risk characteristics.

This Fair Ratio is more tailored than a simple comparison with peers or the industry because it aims to factor in Sarepta Therapeutics’ specific growth drivers, risk profile and financial quality rather than assuming all companies in the group deserve similar multiples. Against that yardstick, the current P/E of 33.75x versus a Fair Ratio of 10.74x suggests the stock screens as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Sarepta Therapeutics Narrative

Earlier it was mentioned that there is an even better way to think about valuation, and on Simply Wall St this takes the form of Narratives. You choose a story for Sarepta Therapeutics, link that story to explicit forecasts for revenue, earnings and margins, and arrive at your own Fair Value that can be compared with the current price to decide whether you see the stock as attractive or not.

Each Narrative is available on the Community page and works as an accessible toolkit. It connects a company’s qualitative story to a set of numbers that update automatically when new information such as news, guidance or earnings arrives.

For Sarepta Therapeutics, one investor might align with a cautious Narrative that assumes a Fair Value close to US$6.15 and focuses on risks from regulatory scrutiny, gene therapy infusion delays and revenue concentration. Another investor might choose a more constructive Narrative that points to a higher Fair Value near US$37.42 based on expectations around ELEVIDYS access, siRNA data and broader pipeline contributions. The platform helps you see exactly which assumptions lead to each view.

For Sarepta Therapeutics, however, we will make it really easy for you with previews of two leading Sarepta Therapeutics Narratives:

Fair Value: US$21.65

Implied pricing vs this Fair Value: about 3.9% undervalued at the last close of US$20.80

Forecast revenue growth rate used in this Narrative: 13.30% decline per year

• Analysts in this camp focus on ELEVIDYS execution improving over time, with operational delays and administrative hurdles gradually easing so more eligible patients can be treated.
• They see added support from label updates, safety and efficacy data, and newer programs like LGMD and siRNA, which together broaden Sarepta Therapeutics’ potential revenue base.
• This Narrative leans on Sarepta Therapeutics moving from current losses toward positive margins, while acknowledging that safety concerns and high research spend remain key risks.

Fair Value: US$6.15

Implied pricing vs this Fair Value: the last close of US$20.80 is a very large premium to this estimate

Forecast revenue growth rate used in this Narrative: 32.59% decline per year

• The bearish view stresses ongoing regulatory scrutiny, safety questions around ELEVIDYS, and administrative delays that could keep treatment volumes and revenue under pressure.
• It highlights reliance on a concentrated Duchenne franchise and capacity constraints at top infusion sites, alongside heavy R&D spend and cash outflows.
• On these assumptions, Sarepta Therapeutics is treated as significantly overvalued, with the investment case hinging on tougher revenue and margin outcomes than the consensus expects.

These two Narratives set out very different futures for the same stock. The tool is designed to help you decide which story, assumptions and risk profile feel closer to your own view of Sarepta Therapeutics.

Do you think there's more to the story for Sarepta Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.